Adaptogen and nootropic are not vague wellness adjectives. Both were coined by named scientists who published explicit criteria — three conditions for an adaptogen in 1969, five for a nootropic in 1972 — and both sets of criteria are still sitting there, unused, while the words appear on packaging. Run the shelf against the actual definitions and the result is uncomfortable: one species has a partial claim to one label, and most have neither.
The adaptogen concept came from Soviet pharmacology: a substance that is essentially non-toxic, acts non-specifically to raise resistance to varied stressors, and normalises function regardless of the direction of the disturbance. The European Medicines Agency's herbal committee examined that concept and concluded it was not sufficiently defined to support medicinal claims, which is why no EU product may legally claim adaptogenic effects. The nootropic concept came from Corneliu Giurgea in 1972 with five criteria including memory enhancement, protection against impairment, and an absence of ordinary psychotropic pharmacology. Of the mushrooms sold under these words, lion's mane has a partial nootropic case from two small trials, reishi has one 132-patient fatigue trial that fits the adaptogen shape, and cordyceps, chaga and Trametes Versicolor have no evidence against either definition.
The words are doing real commercial work, so it is worth knowing exactly what each one was built to mean and who set the bar.
Where "Adaptogen" Came From
From Soviet military and occupational medicine. The term was introduced by Nikolai Lazarev in 1947 and given operational criteria by Brekhman and Dardymov in 1969: an adaptogen must be innocuous at normal doses, must act non-specifically by increasing resistance to a wide range of physical, chemical and biological stressors, and must have a normalising action — correcting a disturbance whichever direction it runs in.
That third criterion is the strange and interesting one. A normalising substance would lower something when it is too high and raise it when it is too low, which is not how most pharmacology behaves and is genuinely difficult to demonstrate in a trial.
Panossian's 2017 review restates the modern position: adaptogens are best understood as stress-response modifiers acting across networks rather than at a single receptor, which he argues makes classical reductionist pharmacology the wrong tool for describing them. That is a reasonable scientific argument. It also makes the category extremely hard to falsify, and categories that cannot be falsified are exactly what marketing departments like.
Why Regulators Refuse the Word
Because of that same problem. The European Medicines Agency's Committee on Herbal Medicinal Products examined the adaptogenic concept and concluded that it was not sufficiently defined in pharmacological or clinical terms to underpin medicinal claims for herbal products.
The practical result is that in the EU, "adaptogen" is not a permitted claim on a food supplement and not a recognised medicinal indication. It survives as descriptive marketing language, which is why you see it on the front of packs and never in the regulated claim text on the back.
Anyone telling you a mushroom is "clinically proven adaptogenic" is using a phrase that the relevant regulator has specifically declined to accept as meaningful.
Where "Nootropic" Came From
From Corneliu Giurgea, the Romanian-Belgian pharmacologist who synthesised piracetam, writing in 1972. His definition was tighter than the adaptogen one, with five conditions. A nootropic should enhance learning and memory; should protect learned behaviour against conditions that disrupt it; should protect the brain against physical or chemical injury; should improve the efficiency of cortical and subcortical control mechanisms; and should lack the pharmacology of ordinary psychotropic drugs — no sedation, no stimulation, no motor effects, very low toxicity.
That last criterion quietly disqualifies a great deal of what is sold as nootropic today. Caffeine fails it. So does anything with a noticeable acute effect, which includes most of what people notice and therefore most of what people repurchase.
Does Lion's Mane Qualify as a Nootropic?
Partially, on two small trials, against two of the five criteria.
Mori's 2009 study is the memory criterion. Thirty Japanese adults aged 50 to 80 with mild cognitive impairment took 3 grams a day of dried powder for 16 weeks; cognitive scores rose significantly against placebo at weeks 8, 12 and 16, and fell significantly again four weeks after stopping. Fifteen people per arm, and the effect did not persist.
Li's 2020 trial runs 49 weeks of erinacine A-enriched mycelium and speaks more to the protection criterion: the significant cognitive decline in that study occurred in the placebo arm, while the treatment arm improved on the Mini-Mental State Examination and held daily function. Our NGF article examines how far the mechanism claim behind it actually reaches.
Nagano's 2010 study gave lion's mane baked into cookies to women for four weeks and recorded reductions in depression and anxiety scores — useful, and also precisely the sort of psychotropic-adjacent effect Giurgea's fifth criterion excludes from the definition.
So: a defensible partial claim on memory and protection, nothing on cortical control mechanisms, and a complication on the purity criterion. That is more than any other mushroom has, and it is not a clean qualification.
Does Reishi Qualify as an Adaptogen?
It has the only trial in the category with the right shape, and it still does not test the criteria.
Tang's 2005 study randomised 132 patients with neurasthenia — an ICD-10 diagnosis of chronic fatigue and weakness — to a Ganoderma lucidum polysaccharide extract at 1,800 mg three times daily or placebo for eight weeks. Sense of fatigue fell 28.3% from baseline against 20.1% on placebo; clinical global impression severity fell 15.5% against 4.9%; and 51.6% of the treatment group were rated more than minimally improved against 24.6% on placebo.
That is a real result on a fatigue endpoint and it fits the intuitive adaptogen story. What it does not do is test non-specific resistance across varied stressors, or demonstrate normalisation in both directions, which are two of Brekhman's three conditions. No mushroom trial has ever been designed to test either.
Everything Else
Cordyceps is sold as an adaptogen and behaves like an ergogenic aid: its human evidence sits on aerobic threshold and exercise metabolism, which is a specific effect on a specific system — the opposite of the non-specificity criterion. Our endurance article covers what those trials measured.
Chaga has no human trial on stress, fatigue or cognition at all. Trametes Versicolor's human evidence is oncology-adjacent immunology and says nothing about either category. Both are routinely labelled adaptogenic anyway.
| Species | Adaptogen criteria met | Nootropic criteria met | Verdict |
|---|---|---|---|
| Lion's mane | Not tested | Memory and protection, partially; fifth criterion contested | The only partial nootropic case |
| Reishi | Non-toxicity only; fatigue trial fits the shape | None | Closest to the adaptogen story, untested on its criteria |
| Cordyceps militaris | Specific, not non-specific | None | Ergogenic, not adaptogenic |
| Chaga | No relevant human trial | None | Label only |
| Trametes Versicolor | No relevant human trial | None | Label only |
| Ashwagandha (for comparison) | Multiple stress and cortisol trials | None | Better adaptogen evidence than any mushroom |
Why Both Labels Survive
Because they solve a marketing problem elegantly. "Adaptogen" promises a benefit without naming an outcome, which means it cannot be disproven and does not trigger a regulated health claim. "Nootropic" borrows the authority of a pharmacological classification while being applied to substances that would fail the classification's own tests.
Neither word is fraudulent. Both are simply empty of the specific information a buyer needs, which is: what changed, in whom, measured how, over how long.
What to Do With This
- Buy the trial, not the label. If a product's real case is a 16-week memory trial, judge it as that — see our lion's mane dosage guide for matching the dose used.
- Treat "adaptogen" as zero information in the EU. The regulator has declined to recognise the category, so the word distinguishes nothing between two products.
- Ask which criterion a product claims to meet. Nobody selling on these words can name Brekhman's three or Giurgea's five, which is itself the answer.
- If stress is the goal, compare against ashwagandha honestly. Its trial record on that endpoint is stronger than any mushroom's — our comparison sets both out.
- Be suspicious of a strong acute effect sold as nootropic. By the original definition, feeling it working counts against the classification.
- Expect maintenance, not accumulation. The lion's mane gains reversed four weeks after stopping, which is a fact about the product you are budgeting for.
The Honest Summary
Two precise scientific terms escaped into marketing and lost their contents on the way. The adaptogen criteria have never been applied to a mushroom because the trials required to test non-specificity and normalisation do not exist. The nootropic criteria have been partially met by exactly one species, in two small studies, with a complication on the criterion that excludes mood-active compounds.
None of that makes the products useless. Reishi's fatigue result and lion's mane's cognition results are real, and both are more interesting than the words printed over them. It does mean that if a pack is selling you a category rather than an endpoint, you are being sold the one thing in this field that has no evidence behind it at all.
Frequently Asked Questions
What is the actual definition of an adaptogen?
Brekhman and Dardymov's 1969 criteria: essentially non-toxic at normal doses, acting non-specifically to raise resistance to a wide range of stressors, and normalising — correcting a disturbance in whichever direction it runs. No mushroom has been tested against the second and third conditions.
Is lion's mane a nootropic?
Partially, by the original 1972 definition. It has human evidence on memory in mild cognitive impairment and on protection against decline over 49 weeks, but no evidence on cortical control mechanisms, and its reported mood effects sit awkwardly with the criterion that excludes ordinary psychotropic action.
Why can't European products claim to be adaptogens?
The European Medicines Agency's herbal committee reviewed the adaptogenic concept and found it insufficiently defined in pharmacological and clinical terms to support medicinal claims. It is therefore not an approved claim for food supplements or a recognised medicinal indication.
Is reishi an adaptogen?
It has the closest thing to supporting evidence: a 132-patient randomised trial in neurasthenia where fatigue fell 28.3% from baseline against 20.1% on placebo over eight weeks. That tests a fatigue endpoint, not the non-specificity or normalisation criteria the category requires.
Are chaga and Trametes Versicolor adaptogens?
There is no human trial on stress, fatigue or cognition for either species, so the label is applied without supporting evidence. Their research records concern other endpoints entirely.
Shop by Evidence, Not by Category
Dried lion's mane (100 g €39, 500 g €169) is the form used in the 16-week cognition trial at 3 g a day; capsules (120 caps €49) hold 0.5 g each. Reishi capsules (120 caps €39, 2 × 120 €70) target the fatigue endpoint that has the trial behind it. Ashwagandha capsules (120 caps €29) are the honest comparison for stress. Browse Focus & Cognition. Free shipping on orders over €50.
Related Articles
- Reishi: Stress and Sleep Guide
- Best Mushrooms for Stress and Cortisol
- Ashwagandha vs Reishi for Stress
- Lion's Mane and NGF: The Human Research
- Best Mushrooms for Focus and Concentration
- Cordyceps for Endurance
- Best Mushrooms for Healthy Aging
Sources
- Giurgea C. [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology]. Actual Pharmacol (Paris). 1972;25:115-156. PubMed 4541214
- Panossian A. Understanding adaptogenic activity: specificity of the pharmacological action of adaptogens and other phytochemicals. Ann N Y Acad Sci. 2017;1401(1):49-64. PubMed 28640972
- European Medicines Agency, Committee on Herbal Medicinal Products. Reflection paper on the adaptogenic concept. EMEA/HMPC/102655/2007. EMA
- Tang W, Gao Y, Chen G, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8(1):53-58. PubMed 15857210
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372. PubMed 18844328
- Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-237. PubMed 20834180
- Li IC, Chang HH, Lin CH, et al. Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020;12:155. PubMed 32581767